Research Briefs: Gore Iliac Branch Trial; Svelte DES Trial; TherOx SSO2 Data

Gore is sponsoring a 60-patient trial of its Excluder iliac branch endoprosthesis. Svelte’s randomized DIRECT II trial of its sirolimus-eluting stent has finished enrollment, and TherOx has positive data on its second-generation SSO2 system for reducing the size of myocardial infarcts.